Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Infliximab in the Treatment of Chinese Subjects With Moderate to Severe Plaque-type Psoriasis
NCT01177800 is registered in ClinicalTrials.gov with Xian-Janssen Pharmaceutical Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Infliximab in the Treatment of Chinese Subjects With Moderate to Severe Plaque-type Psoriasis
- Lead sponsor
- Xian-Janssen Pharmaceutical Ltd.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- February 28, 2009
- Completion date
- September 30, 2010
- Enrollment
- 129 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.